McKesson Expands Gene Therapy Role With Nanoscope InspiroGene Partnership

Simply Wall St.05-30

McKesson (NYSE:MCK) has been selected by Nanoscope Therapeutics to provide U.S. commercialization and supply chain support for a retinal gene therapy through its InspiroGene service. The collaboration...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2639967033?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/288195-main-header/1756206015044","is_english":true,"pubTime":"2026-05-30 04:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2639967033","market":"us","top_or_hot":-1,"title":"McKesson Expands Gene Therapy Role With Nanoscope InspiroGene Partnership","media":"Simply Wall St.","content":"<div>\n<p>McKesson (NYSE:MCK) has been selected by Nanoscope Therapeutics to provide U.S. commercialization and supply chain support for a retinal gene therapy through its InspiroGene service. The collaboration...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-mck/mckesson/news/mckesson-expands-gene-therapy-role-with-nanoscope-inspirogen\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>McKesson Expands Gene Therapy Role With Nanoscope InspiroGene Partnership</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMcKesson Expands Gene Therapy Role With Nanoscope InspiroGene Partnership\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-30 04:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-mck/mckesson/news/mckesson-expands-gene-therapy-role-with-nanoscope-inspirogen><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>McKesson (NYSE:MCK) has been selected by Nanoscope Therapeutics to provide U.S. commercialization and supply chain support for a retinal gene therapy through its InspiroGene service. The collaboration...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-mck/mckesson/news/mckesson-expands-gene-therapy-role-with-nanoscope-inspirogen\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0868494708.USD","symbol_name":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) INC","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-mck/mckesson/news/mckesson-expands-gene-therapy-role-with-nanoscope-inspirogen","article_id":"2639967033","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/288195-main-header/1756206015044"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-mck/mckesson/news/mckesson-expands-gene-therapy-role-with-nanoscope-inspirogen","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2639967033","pubTimestamp":1780085116,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"McKesson (NYSE:MCK) has been selected by Nanoscope Therapeutics to provide U.S. commercialization and supply chain support for a retinal gene therapy through its InspiroGene service.\nThe collaboration centers on a novel optogenetic treatment intended for patients with inherited retinal disease.\nInspiroGene will handle specialty distribution and patient access services as Nanoscope prepares for a potential U.S. launch.\n\nFor investors watching McKesson’s role in specialty medicines, this move...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0868494708.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) INC","LU0861579265.USD":"联博低波幅策略股票基金A","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","LU0314106906.USD":"MANULIFE GF GLOBAL EQUITY \"AA\" (USD) INC","LU0048573561.USD":"FIDELITY AMERICA \"A\" (USD) INC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU0251131958.USD":"FIDELITY AMERICA \"A\" (USD) ACC","LU0251142724.SGD":"Fidelity America A-SGD","LU1983260115.SGD":"Janus Henderson Horizon Global Sustainable Equity A2 SGD-H","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU0124676726.USD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (USD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","BK4585":"ETF&股票定投概念","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","BK4175":"保健护理产品经销商","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","LU0942090050.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD)  INC","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0689626769.HKD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (HKD) ACC","MCK":"麦克森药物批发","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","BK4588":"碎股","LU0742534661.SGD":"Fidelity America A-SGD (hedged)"},"translate_title":"McKesson与Nanoscope InspiroGene合作扩大基因治疗作用","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MCK":1.5},"content_text":"McKesson (NYSE:MCK) has been selected by Nanoscope Therapeutics to provide U.S. commercialization and supply chain support for a retinal gene therapy through its InspiroGene service. The collaboration centers on a novel optogenetic treatment intended for patients with inherited retinal disease. InspiroGene will handle specialty distribution and patient access services as Nanoscope prepares for a potential U.S. launch.  For investors watching McKesson’s role in specialty medicines, this move brings the company further into the gene therapy and orphan drug arena, beyond its core drug distribution operations. The InspiroGene engagement with Nanoscope ties McKesson more directly to emerging optogenetic approaches in retinal care, an area that depends heavily on tight supply chain controls. It also reinforces how NYSE:MCK participates in the complex logistics required for advanced therapies. The partnership gives McKesson additional exposure to a corner of biopharma where products often require high touch patient support and careful distribution. If more gene therapy developers select similar services, it could increase the relevance of McKesson’s specialty infrastructure in future launches. Readers considering NYSE:MCK can monitor how the InspiroGene platform is used by other therapy sponsors over time. Stay updated on the most important news stories for McKesson by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on McKesson. NYSE:MCK Earnings & Revenue Growth as at May 2026 We've flagged 1 risk for McKesson. See which could impact your investment. This agreement gives McKesson another proof point that its specialty-services offering can win contracts in complex therapies where logistics and patient support are critical. InspiroGene’s role spans specialty distribution, pharmacy, and patient-hub activities for Nanoscope’s MOGENRY, which depends on tight cold-chain handling and coordinated patient onboarding. That puts McKesson closer to therapy developers at the commercialization stage, rather than just acting as a downstream distributor, and brings it into a part of healthcare where peers such as AmerisourceBergen (Cencora) and Cardinal Health are also active. AdvertisementHow This Fits Into The McKesson Narrative  The deal lines up with the narrative that McKesson is building out higher value services like patient access, specialty distribution, and commercialization support, which can deepen customer relationships and increase revenue visibility. It also tests the company’s ability to execute in highly complex, personalized therapies, an area where any operational issues could challenge expectations that supply chain sophistication will support margins over time. Gene therapy specific capabilities, such as optogenetics in retinal disease, are not a core focus of the existing narrative, so investors may want to consider how these niche services fit alongside areas like biosimilars, oncology, and automation in distribution centers.  Knowing what a company is worth starts with understanding its story.\nCheck out one of the top narratives in the Simply Wall St Community for McKesson to help decide what it's worth to you. The Risks and Rewards Investors Should Consider  ⚠️ Handling complex gene therapies increases operational and regulatory risk if cold-chain or patient safety standards are not met. ⚠️ Concentration in highly specialized therapies can expose McKesson to product specific or reimbursement changes if a therapy’s uptake or coverage is different from expectations. 🎁 Expanding into commercialization and patient-support services for advanced therapies can strengthen McKesson’s role with biopharma clients and support more recurring service revenue. 🎁 Success with Nanoscope could help McKesson compete for similar contracts against peers such as Cencora and Cardinal Health, reinforcing the value of its specialty infrastructure.  What To Watch Going Forward From here, focus on whether McKesson wins additional gene-therapy or orphan-drug mandates through InspiroGene, how often MOGENRY is used once approved, and any disclosures about specialty-services volumes or margins. Investors can also track whether analysts reference this agreement when discussing McKesson’s mix of distribution versus higher value services, particularly as other healthcare distributors look to grow in similar areas. To ensure you're always in the loop on how the latest news impacts the investment narrative for McKesson, head to the\ncommunity page for McKesson to never miss an update on the top community narratives.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2639967033","isCrawlerRequest":true}